Stockscreener 앱 받기
0.3672
1.13%
0.0041
시간 외 거래:
.35
-0.0172
-4.68%
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
94,531 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Purchased by Pallas Capital Advisors LLC - Defense World
Mersana Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Two Sigma Investments LP Has $302,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of “Buy” by Brokerages - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Nuveen Asset Management LLC - Defense World
Bank of America Corp DE Sells 36,084 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Short Interest Up 21.4% in May - Defense World
Millennium Management LLC Increases Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at William Blair - Defense World
Mersana reports promising Phase 1 ADC trial results By Investing.com - Investing.com South Africa
Mersana reports promising Phase 1 ADC trial results - Investing.com India
Mersana Therapeutics Reports Additional Positive Interim Phase 1 - GuruFocus
Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data - GuruFocus
Mersana Therapeutics Reports Encouraging Interim Phase 1 Results for Emiltatug Ledadotin in B7-H4 High Tumors at ASCO 2025 - Nasdaq
Mersana Therapeutics Reports Additional Positive Interim - GlobeNewswire
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in ... - Eagle-Tribune
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - Yahoo Finance
Mersana Therapeutics at TD Cowen Summit: Strategic Updates on Oncology Innovations - Investing.com Canada
Deutsche Bank AG Has $1.20 Million Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
D. E. Shaw & Co. Inc. Sells 477,992 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
BNP Paribas Financial Markets Has $516,000 Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Is Now The Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - Stocksregister
Mersana Therapeutics to Present at Upcoming Investor Conferences - GuruFocus
Mersana Therapeutics Showcases Cancer Drug Pipeline at Goldman Sachs and TD Cowen Healthcare Summits - Stock Titan
Cubist Systematic Strategies LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World
Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World
Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN
Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates - MSN
MRSN: Truist Securities Raises Price Target for Mersana Therapeutics | MRSN Stock News - GuruFocus
MRSN: Guggenheim Reiterates Buy Rating with $5 Price Target | MRSN Stock News - GuruFocus
Mersana Therapeutics (MRSN) Target Price Increased by Truist | M - GuruFocus
Mersana Therapeutics price target raised to $10 from $9 at Truist - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating - marketscreener.com
Truist raises Mersana stock target to $10, maintains Buy rating By Investing.com - Investing.com Nigeria
Truist raises Mersana stock target to $10, maintains Buy rating - Investing.com Australia
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights - GuruFocus
Earnings call transcript: Mersana Therapeutics reports Q1 2025 loss, stock up 6.14% - Investing.com Nigeria
Mersana Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CORRECTIONMersana Therapeutics Provides Business Update and A - GuruFocus
Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView
Mersana Cancer Drug Shows Strong 31% Response Rate in Latest Trial Data, Reports Q1 Financial Results - Stock Titan
1.91%
1.17%
자본화:
|
볼륨(24시간):